Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00359762
Status:
COMPLETED
Last Update Posted:
2015-09-15
First Post:
2006-07-31
Brief Title:
Exenatide Versus Glimepiride in Patients With Type 2 Diabetes
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin EUREXA European Exenatide Study
Status:
COMPLETED
Status Verified Date:
2015-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study assesses the effects of twice-daily subcutaneous injection exenatide versus treatment with sulfonylurea glimepiride on long-term glycemic control and beta-cell function
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None